AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20974335 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocryl (poly(glycolide‐co‐ε‐caprolactone))
Number of subjects: 80
Study 20974335 — intervention group
Group type: COMPARATOR
Intervention: Dexon
Number of subjects: 80
Study 20974335 — intervention group
Group type: COMPARATOR
Intervention: Polysorb
Number of subjects: 80
Study 20974335 — intervention group
Group type: COMPARATOR
Intervention: Maxon
Number of subjects: 80
Study 18518694 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-impregnated shunt catheters (AISCs)
Number of subjects: 317
Study 18518694 — intervention group
Group type: COMPARATOR
Intervention: Non-AISC (control group)
Number of subjects: 317
Study 16077295 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol‐remifentanil (group P)
Number of subjects: 120
Study 16077295 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane‐remifentanil (group D)
Number of subjects: 120
Study 16077295 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane‐remifentanil (group S)
Number of subjects: 120
Study 16077295 — intervention group
Group type: COMPARATOR
Intervention: All groups (P, D, S)
Number of subjects: 120
Study 12594971 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 593
Study 12594971 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 593
Study 10615723 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Behavioral Couples Therapy (ABCT)
Number of subjects: 90
Study 10615723 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse Prevention plus ABCT (RP/ABCT)
Number of subjects: 90
Study 10615723 — intervention group
Group type: COMPARATOR
Intervention: Alcoholics Anonymous plus ABCT (AA/ABCT)
Number of subjects: 90
Study 10615723 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (ABCT, AA/ABCT, RP/ABCT)
Number of subjects: 90
Study 8546437 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (600 mg/day) supplementation
Number of subjects: 56
Study 8546437 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 g/day) supplementation
Number of subjects: 56
Study 8546437 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 56
Study 2039705 — intervention group
Group type: EXPERIMENTAL
Intervention: MMM (mitozantrone 8 mg m‐2 i.v. q 3 weekly, methotrexate 35 mg m‐2 i.v. q 3 weekly, mitomycin‐C 8 mg m‐2 i.v. q 6 weekly)
Number of subjects: 112
Study 2039705 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide 100 mg orally, days 1‐14, methotrexate 35 mg m‐2 i.v., days 1 and 8, 5‐FU 1,000 mg i.v., days 1 and 8, q 4 weekly)
Number of subjects: 112
Study 2039705 — intervention group
Group type: EXPERIMENTAL
Intervention: MMM
Number of subjects: 112
Study 2039705 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 112
Study 7302312 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention program to modify coronary risk profile
Number of subjects: 0
Study 7302312 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31873623 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µm SNSPDs
Number of subjects: 0
Study 31873623 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 µm SNSPDs
Number of subjects: 0
Study 28346570 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 4000 (10-30 g/day)
Number of subjects: 245
Study 28346570 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (10-30 g/day)
Number of subjects: 245
Study 28346570 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 4000
Number of subjects: 245
Study 28346570 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 245
Study 25974999 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning
Number of subjects: 191
Study 25974999 — intervention group
Group type: COMPARATOR
Intervention: Control group (no remote ischaemic conditioning)
Number of subjects: 191
Study 23400747 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) 5 mg followed by LEX 500 mg
Number of subjects: 24
Study 23400747 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin (LEX) 500 mg alone
Number of subjects: 24
Study 23400747 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil (CXM) 500 mg alone
Number of subjects: 24
Study 20592663 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily lithium carbonate
Number of subjects: 83
Study 20592663 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily lithium carbonate
Number of subjects: 83
Study 19796554 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg
Number of subjects: 24
Study 19796554 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 16708583 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO 160/120
Number of subjects: 257
Study 16708583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 15387514 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Pedagogy class
Number of subjects: 0
Study 15387514 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11673197 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 120
Study 9832076 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation
Number of subjects: 58
Study 9832076 — intervention group
Group type: COMPARATOR
Intervention: No LCPUFA
Number of subjects: 58
Study 7661538 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine 8-vasopressin at a concentration of 0.01 IU/ml chilled saline
Number of subjects: 20
Study 7661538 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied to be epinephrine)
Number of subjects: 20
Study 2782647 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 20
Study 2782647 — intervention group
Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 20
Study 813488 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 74,917 aerosol
Number of subjects: 10
Study 813488 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate powder
Number of subjects: 10
Study 813488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31302314 — intervention group
Group type: EXPERIMENTAL
Intervention: Online personalized feedback intervention (PFI)
Number of subjects: 204
Study 31302314 — intervention group
Group type: COMPARATOR
Intervention: Online personalized normative feedback-only condition (PNF-only)
Number of subjects: 204
Study 28549309 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (SC) via single-use injection device (SID)
Number of subjects: 0
Study 28549309 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (SC) via hand-held syringe
Number of subjects: 0
Study 28549309 — intervention group
Group type: COMPARATOR
Intervention: Intravenous trastuzumab (IV)
Number of subjects: 0
Study 28549309 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching between SC and IV trastuzumab
Number of subjects: 0
Study 24448345 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg intravenously every 4 weeks plus methotrexate (MTX)
Number of subjects: 91
Study 24448345 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 91
Study 23653934 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined probiotic bifiform (Ferrosan) containing Bifidobacterium longum 107, Enterococcus faecium 107 as one capsule t.i.d. for 14 days, along with basic therapy (mesim forte as one tablet t.i.d., no-spa, 40 mg, t.i.d.)
Number of subjects: 138
Study 23653934 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy in combination with placebo
Number of subjects: 138
Study 21262079 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-conditioning
Number of subjects: 60
Study 21262079 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic pre-conditioning
Number of subjects: 60
Study 21262079 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 19280279 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 + PALD
Number of subjects: 117
Study 19280279 — intervention group
Group type: COMPARATOR
Intervention: D2
Number of subjects: 117
Study 16411969 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 15 Hz rTMS of the left dorsolateral prefrontal cortex (LDLPFC) (110% of motor threshold, 3000 pulses per session)
Number of subjects: 30
Study 16411969 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 5 Hz rTMS of the primary motor cortex (M1)-mouth area (90% MT, 2250 pulses per session)
Number of subjects: 30
Study 16411969 — intervention group
Group type: COMPARATOR
Intervention: Sham 15 Hz rTMS of the left dorsolateral prefrontal cortex (LDLPFC)
Number of subjects: 30
Study 15142071 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser palatoplasty
Number of subjects: 83
Study 15142071 — intervention group
Group type: COMPARATOR
Intervention: Uvulectomy with punctate palatal diathermy
Number of subjects: 83
Study 11156862 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/d)
Number of subjects: 111
Study 11156862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 9164774 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg of zinc as zinc sulfate daily for 7 months)
Number of subjects: 89
Study 9164774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 7958144 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinylestradiol + 150 micrograms desogestrel (EE+D)
Number of subjects: 44
Study 7958144 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol + 75 micrograms gestodene (EE+G)
Number of subjects: 44
Study 7958144 — intervention group
Group type: COMPARATOR
Intervention: Both groups (EE+D and EE+G)
Number of subjects: 44
Study 3332568 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous miconazole
Number of subjects: 180
Study 3332568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 30865526 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 0.5 mg
Number of subjects: 5119
Study 30865526 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 1.0 mg
Number of subjects: 5119
Study 30865526 — intervention group
Group type: COMPARATOR
Intervention: comparators (placebo, sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine, dulaglutide 0.75 or 1.5 mg)
Number of subjects: 5119
Study 28216183 — intervention group
Group type: EXPERIMENTAL
Intervention: H4:IC31 vaccine (5, 15, 50μg of H4 with 500nmol IC31 adjuvant)
Number of subjects: 106
Study 28216183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 26222550 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive condition
Number of subjects: 200
Study 26222550 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 200
Study 24212393 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Story Memory Technique (mSMT), a 10-session behavioral intervention
Number of subjects: 86
Study 24212393 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Story Memory Technique (mSMT)
Number of subjects: 86
Study 24212393 — intervention group
Group type: EXPERIMENTAL
Intervention: booster sessions
Number of subjects: 86
Study 24212393 — intervention group
Group type: COMPARATOR
Intervention: placebo control
Number of subjects: 86
Study 21674151 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin 20 mg/70 kg
Number of subjects: 18
Study 21674151 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin 30 mg/70 kg
Number of subjects: 18
Study 21674151 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (ascending dose sequence)
Number of subjects: 18
Study 21674151 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (20 and 30 mg/70 kg)
Number of subjects: 18
Study 21674151 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (all doses)
Number of subjects: 18
Study 21674151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 18320185 — intervention group
Group type: EXPERIMENTAL
Intervention: FM‐VP4 400 mg/day
Number of subjects: 130
Study 18320185 — intervention group
Group type: EXPERIMENTAL
Intervention: FM‐VP4 100 mg/day
Number of subjects: 130
Study 18320185 — intervention group
Group type: EXPERIMENTAL
Intervention: FM‐VP4 200 mg/day
Number of subjects: 130
Study 18320185 — intervention group
Group type: EXPERIMENTAL
Intervention: FM‐VP4 800 mg/day
Number of subjects: 130
Study 18320185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 16234840 — intervention group
Group type: EXPERIMENTAL
Intervention: Water (H2O)
Number of subjects: 21
Study 16234840 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate/electrolyte drink (CHOE)
Number of subjects: 21
Study 16234840 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 21
Study 12514671 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA occlusion during CABG surgery
Number of subjects: 2500
Study 12514671 — intervention group
Group type: COMPARATOR
Intervention: No LAA occlusion during CABG surgery (Control)
Number of subjects: 2500
Study 12514671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot trial assessing LAA occlusion
Number of subjects: 2500
Study 11061766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy for threshold ROP
Number of subjects: 1454
Study 11061766 — intervention group
Group type: COMPARATOR
Intervention: Unfavorable visual acuity
Number of subjects: 1454
Study 11061766 — intervention group
Group type: COMPARATOR
Intervention: No ROP
Number of subjects: 1454
Study 11061766 — intervention group
Group type: COMPARATOR
Intervention: Threshold ROP
Number of subjects: 1454
Study 8640040 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat-salt solution (WSS)
Number of subjects: 326
Study 8640040 — intervention group
Group type: COMPARATOR
Intervention: World Health Organization recommended glucose-oral rehydration salts (G-ORS)
Number of subjects: 326
Study 1848161 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline
Number of subjects: 12
Study 1848161 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dipyridamole
Number of subjects: 12
Study 1848161 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 12
Study 6344626 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use
Number of subjects: 1239
Study 31486915 — intervention group
Group type: EXPERIMENTAL
Intervention: Biceps tenotomy
Number of subjects: 34
Study 31486915 — intervention group
Group type: COMPARATOR
Intervention: Biceps tenodesis
Number of subjects: 34
Study 28958900 — intervention group
Group type: EXPERIMENTAL
Intervention: TMR (1120 kcal/d from shakes)
Number of subjects: 32
Study 28958900 — intervention group
Group type: COMPARATOR
Intervention: TD (iso-caloric portion control)
Number of subjects: 32
Study 28958900 — intervention group
Group type: COMPARATOR
Intervention: TMR vs. TD
Number of subjects: 32
Study 26824413 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (dosage and duration not specified)
Number of subjects: 82
Study 26824413 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 82
Study 25225746 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high-dose erythropoietin (400 IU/kg)
Number of subjects: 75
Study 25225746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 22531305 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) insufflation only at the time of scope withdrawal (CW)
Number of subjects: 100
Study 22531305 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) insufflation throughout the procedure (C)
Number of subjects: 100
Study 22531305 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation (A)
Number of subjects: 100
Study 19362288 — intervention group
Group type: EXPERIMENTAL
Intervention: HM-VAC (homemade vacuum dressing)
Number of subjects: 40
Study 19362288 — intervention group
Group type: COMPARATOR
Intervention: WET (conventional saline-soaked gauze dressings)
Number of subjects: 40
Study 19362288 — intervention group
Group type: EXPERIMENTAL
Intervention: HM-VAC
Number of subjects: 40
Study 19362288 — intervention group
Group type: COMPARATOR
Intervention: WET
Number of subjects: 40
Study 17293572 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex coils
Number of subjects: 223
Study 17293572 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical coils
Number of subjects: 223
Study 17293572 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex and helical coils
Number of subjects: 223
Study 17293572 — intervention group
Group type: COMPARATOR
Intervention: Generalized estimating equations analysis
Number of subjects: 223
Study 11408781 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + MPA
Number of subjects: 27
Study 11408781 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + NETA
Number of subjects: 27
Study 11408781 — intervention group
Group type: COMPARATOR
Intervention: E2 alone
Number of subjects: 27
Study 11408781 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + MPA and E2 + NETA
Number of subjects: 27
Study 11408781 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + progestagen
Number of subjects: 27
Study 11408781 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestagen phase
Number of subjects: 27
Study 15102391 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic cream (EMLA)
Number of subjects: 14
Study 15102391 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 14
Study 8508427 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FAMTX treatment (5-fluorouracil, doxorubicin, methotrexate at 1000 mg/m2)
Number of subjects: 40
Study 8508427 — intervention group
Group type: COMPARATOR
Intervention: Supportive measures only (control group)
Number of subjects: 40
Study 3330186 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (2.35 mg x 2, 120 min apart)
Number of subjects: 8
Study 3330186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline (6 mg/kg followed by 0.5 mg/kg/hr infusion)
Number of subjects: 8
Study 3330186 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nebulised salbutamol and intravenous aminophylline
Number of subjects: 8
Study 29498924 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (RE)
Number of subjects: 360
Study 29498924 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 800 mg/d
Number of subjects: 360
Study 29498924 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 360
Study 27472856 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted pendulum exercises (1.5 kilograms hand held dumbbell)
Number of subjects: 34
Study 27472856 — intervention group
Group type: EXPERIMENTAL
Intervention: Un-weighted pendulum exercises (free of weight)
Number of subjects: 34
Study 27472856 — intervention group
Group type: COMPARATOR
Intervention: Weighted and un-weighted pendulum exercises
Number of subjects: 34
Study 24425454 — intervention group
Group type: COMPARATOR
Intervention: Traditional Exercise (TE)
Number of subjects: 38
Study 24425454 — intervention group
Group type: COMPARATOR
Intervention: Horse Exercise (HE)
Number of subjects: 38
Study 24425454 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study 24029567 — intervention group
Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol (HDL-C) in young men with AMI
Number of subjects: 278
Study 24029567 — intervention group
Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol (HDL-C) in young men with AMI with smoking history
Number of subjects: 278
Study 24029567 — intervention group
Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol (HDL-C) in normal weight young AMI men
Number of subjects: 278
Study 24029567 — intervention group
Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol (HDL-C) in single lesions group
Number of subjects: 278
Study 24029567 — intervention group
Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol (HDL-C) as a protective factor
Number of subjects: 278
Study 24029567 — intervention group
Group type: EXPERIMENTAL
Intervention: Low density lipoprotein cholesterol (LDL-C) and essential hypertension as independent risk factors
Number of subjects: 278
Study 20577147 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. bolus injection of Escherichia coli endotoxin (LPS; 2 ng/kg)
Number of subjects: 7
Study 20577147 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 7
Study 18940376 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback indicating correct detection of mobile phone signals (n=31)
Number of subjects: 69
Study 18940376 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback indicating incorrect detection of mobile phone signals (n=27)
Number of subjects: 69
Study 16849068 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-rotor stripping (ARS) treated surfaces
Number of subjects: 40
Study 16849068 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control) surfaces
Number of subjects: 40
Study 16849068 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall caries risk (DMFT and DMFS scores)
Number of subjects: 40
Study 12711235 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysplastic hips
Number of subjects: 0
Study 12711235 — intervention group
Group type: COMPARATOR
Intervention: Normal hips
Number of subjects: 0
Study 12711235 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with Harris hip score
Number of subjects: 0
Study 10754477 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH(1-29)NH2 at 0.15 microg/kg
Number of subjects: 5
Study 10754477 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH(1-29)NH2 at 1.0 microg/kg
Number of subjects: 5
Study 10754477 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH(1-29)NH2 (incremental doses)
Number of subjects: 5
Study 8831308 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg bupivacaine, 3 mL of 0.5% spinal bupivacaine in 8% dextrose
Number of subjects: 60
Study 8831308 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bupivacaine, 2 mL of the 0.5% spinal bupivacaine + 1 mL saline
Number of subjects: 60